QuantRx’s Diagnostic Reader (OTC:QTXB)
QuantRx Biomedical Corporation (OTC:QTXB) has announced that the Company will soon demonstrate its latest technology at the MEDICA 2009. The Company announced that QuantRx has developed a new point-of-care medical device that will introduce for the first time its flagship diagnostic reader device called as Q-Reader. The Company will show its latest diagnostic device at the world’s leading medical trade fair where they will be hosting their milestone event and will present their Q-Reader diagnostic reader device. The Company has always been into the development and commercialization of broad based diagnostics products and latest devices.
QuantRx Biomedical Corporation has always put their expertise in the discovery of diagnostic platforms and commercialization of products for use by healthcare professionals and consumers. The Company is more focused on providing more accurate, reliable and faster diagnoses that result in improved patient care. The strategy of the Company targets significant market opportunities that is estimated to be in excess of US$5 billion worldwide and the Company wants to debut their product at the Medica 2009 where they can present an extraordinary point-of-care system that is capable of significantly improving medical diagnostic procedures while potentially lowering healthcare costs and expenditures.
The Company has been developing a platform of POC devices to provide more facilities for diagnosis of critical metabolic markers, especially those related with thyroid disease, therapeutic drugs, malignant cancers and other medically relevant conditions. This unique platform technology combines the sensitivity of QuantRx RapidSense Technology with the ultra-portable Q-Reader that enables the use of any biological sample like blood, urine, vaginal fluids and saliva to deliver laboratory results to the primary care provider within minutes. CEO of QuantRx said that their products are made to provide front line information needed by the healthcare professionals and consumers to aid timely diagnosis and treatment in order to provide greater patient convenience.

By Jyotsna Ramani on 11/09/2009 10:05 am PST -- Biotech